BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
Key Highlights
- ➤BGLC signs exclusive ten-year Malaysian healthcare CogniAI licence, pending closing and approvals
- ➤BGLC will issue 410,000 shares for US$3.5 million licence consideration, with no cash payment
- ➤BGLC will issue 150,000 shares for 500,000 RYET shares, totaling 560,000 shares
- ➤RYET receives 10% of defined technology receipts collected, with no minimum royalty or platform fee
- ➤Malaysia raised public healthcare digitalization allocation to RM1 billion for 150 hospitals and 2,000-plus clinics
Expert Statements
Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp.
“With CogniAI we would not be starting from a blank page. The platform exists and is in commercial use, and our job is to build the applications around it. Malaysia is putting real money into taking public healthcare records digital, and that is where we intend to go first.”
Maggie Fu, Chief Executive Officer of Ruanyun Edai Technology Inc.
“BioNexus knows the Malaysian market and its healthcare providers, and that local knowledge is what turns a platform into working applications. We built CogniAI to read and organize records at scale, and we look forward to supporting BioNexus as it takes the platform into healthcare.”
Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp.
“We structured the agreement to keep cash in the business. RYET is taking its licence consideration in our shares and a royalty only on what we collect, so it does well only if we do. The next step is practical. We take delivery, test the technology, and take it to the people running Malaysia's healthcare digitalization.”
KUALA LUMPUR, Malaysia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("Company" or "BGLC") today announced plans to build AI applications for Malaysian healthcare, following the signing of a definitive agreement with Ruanyun Edai Technology Inc. (Nasdaq: RYET) on October 5, 2026 for an exclusive Malaysian healthcare licence to RYET's CogniAI artificial intelligence platform. BGLC's first target is Malaysia's public healthcare digitalization programme, which covers 150 hospitals and more than 2,000 health clinics. Closing and the contemplated share issuances remain pending.
"With CogniAI we would not be starting from a blank page," said Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp. "The platform exists and is in commercial use, and our job is to build the applications around it. Malaysia is putting real money into taking public healthcare records digital, and that is where we intend to go first."
Get started
Create a free account to read the full story.